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As a principal intracellular receptor for nitric oxide (NO),
soluble guanylate cyclase (sGC) plays a fundamental role
in cardiovascular homeostasis and disease. However,
there is a paucity of information regarding expressional
regulation of sGC in the vasculature. Since the enzyme is
an obligatory heterodimer composed of α and β subunits
[1], we investigated the transcriptional regulation of
human sGC α1 and β1 genes in human aortic smooth mus-
cle cells (HASMCs).
The 5' flanking regions harbouring 0.3–3.0 kb of both α1
and β1 sGC genes were isolated and analysed for promoter
activity by using luciferase-reporter constructs. Upstream
fragments of 0.3 kb and 0.5 kb exhibited maximal pro-
moter activity for the α1 and β1 sGC promoters, respec-
tively (Figure 1). The functional significance of consensus
transcriptional factor (TF) binding sites proximal to the
transcriptional start site was investigated by site-specific
deletions in both 0.3 kb (α1 sGC) and 0.5 kb (β1 sGC) pro-
moter fragments. Putative binding sites for the α1 (c-Myb,
NFAT, GABF) and β1 (NFκB, Sp-1, CBF) sGC promoters
were studied. Preliminary data reveal that the activity of
the constructs containing deletions of these TF binding
sites was significantly altered in each case, suggesting that
the analysed binding sites are major determinants of the
α1 and β1 sGC promoter activity in HASMCs. Electro-
phoretic mobility-shift assay (EMSA) and immunoblot
analyses of proteins bound to biotinylated EMSA probes
will be performed to confirm the interaction of these fac-
tors with the corresponding sGC promoter.
These data therefore provide a systematic, comparative
analysis of human α1 and β1 sGC promoter regulation in
HASMCs and thereby identify potentially important fac-
tors regulating human sGC expression within a cell system
relevant to cardiovascular physiology and pathology.
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Promoter activity of α1 and β1 human sGC luciferase reporter constructs analysed in HASMCs. Promoter activity for each con-
struct was measured in relative (firefly/renilla luciferase) light units. Results are expressed as mean ± SEM (n = 4).Page 2 of 3
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